Gimoti

Gastroparesis, Aerophagy, Migraine + 23 more

Treatment

4 FDA approvals

20 Active Studies for Gimoti

What is Gimoti

Metoclopramide

The Generic name of this drug

Treatment Summary

Metoclopramide is a medication used to treat nausea and vomiting caused by diabetic gastroparesis, a condition that affects the stomach's ability to empty. It can also be used to treat gastroesophageal reflux disease (GERD) or prevent nausea or vomiting caused by chemotherapy or certain medical procedures. Metoclopramide is available as an oral tablet or liquid solution and can be given intravenously. It was approved by the FDA in 1980 and works by blocking dopamine receptors in the body, without increasing gastric acid secretion.

Metoclopramide

is the brand name

image of different drug pills on a surface

Gimoti Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Metoclopramide

Metoclopramide

1985

199

Approved as Treatment by the FDA

Metoclopramide, commonly known as Metoclopramide, is approved by the FDA for 4 uses including Gastroesophageal reflux disease and Gastroesophageal Reflux Disease (GERD) .

Gastroesophageal reflux disease

Gastroesophageal Reflux Disease (GERD)

Failed conventional therapy

Gastroparesis

Effectiveness

How Gimoti Affects Patients

Metoclopramide helps food move through the stomach by loosening the lower esophageal sphincter (LES). It can also reduce nausea and vomiting. Metoclopramide also helps the stomach to move food without increasing bile, stomach acid, or pancreatic secretions. Taking this drug for more than twelve weeks can cause tardive dyskinesia, dystonia, and akathisia, so it should not be taken for long periods of time.

How Gimoti works in the body

Metoclopramide works to prevent nausea and vomiting by blocking dopamine and serotonin receptors in your brain's chemoreceptor trigger zone. It also helps move food through your digestive system faster by blocking certain receptors and increasing the release of acetylcholine, which helps contract your stomach muscles. Finally, it blocks a type of receptor that dopamine binds to, causing relaxation in your digestive system.

When to interrupt dosage

The prescribed dosage of Gimoti is dependent upon the diagnosed affliction, including Nausea, Intubation (procedure) and Gastroesophageal Reflux Disease (GERD). The measure of dosage changes, depending on the method of delivery (e.g. Spray or Tablet, orally disintegrating) featured in the following table.

Condition

Dosage

Administration

Nausea

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

gastric emptying for radiologic procedures

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Therapeutic procedure

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Gastric Motility Disorder

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

prophylaxis of Hiccups

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

meteorism

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Nausea

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Failed conventional therapy

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Acute Coryza

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Nausea

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Hyperacidity

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

radiation therapy induced nausea and vomiting

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Aerophagy

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Flatulence

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Indigestion

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Gastrointestinal distress

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Hiccup

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Nausea

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Pharmacotherapy

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Intubation (procedure)

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Warnings

Gimoti Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Metoclopramide may interact with Pulse Frequency

Mechanical Intestinal Obstruction

Do Not Combine

Gastrointestinal Hemorrhage

Do Not Combine

Gastrointestinal Perforation

Do Not Combine

Paraganglioma

Do Not Combine

Tardive Dyskinesia

Do Not Combine

Pharmaceutical Preparations

Do Not Combine

Pheochromocytoma

Do Not Combine

Parkinson's Disease

Do Not Combine

Depression

Do Not Combine

Epilepsy

Do Not Combine

Gastrectomy

Do Not Combine

Dystonia

Do Not Combine

Feeling suicidal (finding)

Do Not Combine

There are 20 known major drug interactions with Gimoti.

Common Gimoti Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

The risk or severity of adverse effects can be increased when Metoclopramide is combined with Acepromazine.

Aceprometazine

Major

The risk or severity of adverse effects can be increased when Metoclopramide is combined with Aceprometazine.

Acetophenazine

Major

The risk or severity of adverse effects can be increased when Metoclopramide is combined with Acetophenazine.

Alimemazine

Major

The risk or severity of adverse effects can be increased when Metoclopramide is combined with Alimemazine.

Amisulpride

Major

The risk or severity of adverse effects can be increased when Metoclopramide is combined with Amisulpride.

Gimoti Toxicity & Overdose Risk

The maximum toxic dose of metoclopramide in rats has been found to be 750mg/kg. Symptoms of an overdose include drowsiness, confusion, and muscular disorders. Medications typically used to treat Parkinson's disease or anticholinergic drugs may alleviate these muscular symptoms, which usually disappear within 24 hours. Infants who overdose on the oral solution of metoclopramide often experience seizures, muscular disorders, and lethargy. Methemoglobinemia has been reported in premature and full-term babies after a metoclopramide overdose and can be treated with intravenous methylene blue, though this

Gimoti Novel Uses: Which Conditions Have a Clinical Trial Featuring Gimoti?

113 active clinical trials are currently investigating the potential of Gimoti as a treatment for Migraine, Nausea and Pharmacotherapeutic applications.

Condition

Clinical Trials

Trial Phases

Gastroparesis

15 Actively Recruiting

Phase 3, Not Applicable, Phase 1, Early Phase 1

Migraine

51 Actively Recruiting

Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1

Gastric Acid

0 Actively Recruiting

Gastroesophageal Reflux Disease (GERD)

9 Actively Recruiting

Not Applicable, Phase 2

Flatulence

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

Pharmacotherapy

0 Actively Recruiting

Indigestion

6 Actively Recruiting

Phase 3, Not Applicable, Phase 2

radiation therapy induced nausea and vomiting

0 Actively Recruiting

Nausea

0 Actively Recruiting

Gastrointestinal distress

9 Actively Recruiting

Phase 2, Early Phase 1, Phase 1, Phase 3, Not Applicable, Phase 4

Hiccup

0 Actively Recruiting

Failed conventional therapy

0 Actively Recruiting

meteorism

0 Actively Recruiting

Nausea

0 Actively Recruiting

Gastric Motility Disorder

0 Actively Recruiting

Aerophagy

0 Actively Recruiting

Intubation (procedure)

0 Actively Recruiting

gastric emptying for radiologic procedures

0 Actively Recruiting

prophylaxis of Hiccups

0 Actively Recruiting

Gimoti Reviews: What are patients saying about Gimoti?

5

Patient Review

4/7/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

I was really impressed with how quick this worked and how easy it was to use.

5

Patient Review

4/20/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

This product has made a huge difference for me. It's much easier to use than pills, and just as effective.

5

Patient Review

4/29/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

This was a great treatment for me and I would highly recommend it to others!

5

Patient Review

4/16/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

I've tried a lot of different things over the years to help with my gastroparesis, but this is by far the best I've found. Gimoti has made a total step change in my condition and I feel like I'm finally winning the battle against this terrible disease.

5

Patient Review

4/16/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

This was a huge help in reducing my nausea. It's also much more consistent than the pill form of Reglan, which I've used in the past. The nose spray is easy to use and works quickly, which is great.

5

Patient Review

4/19/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

So easy to use and very convenient. I just started using it and already see a difference.

5

Patient Review

4/18/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

I've been on this medication for about a month and it's going really well!

5

Patient Review

4/13/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

So far, I've been taking this medication three times a day for two months and I haven't experienced any negative side effects. Hopefully I'll be able to keep using it long-term!

5

Patient Review

4/12/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

I'm really impressed with this medication. So far, I haven't experienced any negative side effects.

5

Patient Review

4/8/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

When I was too sick to function, this medication really helped me out. Not only that, but it alleviated my nausea quickly.

5

Patient Review

4/12/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

So far, I'm having much better results with this treatment than with oral metoclopramide.

5

Patient Review

4/30/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

Symptom control has been much more consistent for me since starting this treatment three weeks ago.

5

Patient Review

4/13/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

I had a great experience with this product! I usually have difficulty using Reglan, but this one was much better.

4.3

Patient Review

4/14/2021

Gimoti for Stomach Muscle Paralysis and Decreased Function from Diabetes

I found the spray to be more effective than taking the pill form of this medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about gimoti

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does metoclopramide make you drowsy?

"Some potential side effects of metoclopramide are drowsiness and excessive tiredness. If you experience either of these symptoms, be sure to let your doctor know."

Answered by AI

What is Gimoti used for?

"A person with diabetes may experience a complication where their stomach digestion has slowed down. This condition is called diabetic gastroparesis. Gimoti (metoclopramide) is a nasal spray that can help treat this condition. Currently, it is only available as a brand-name product and is usually more expensive than alternative medications."

Answered by AI

How does metoclopramide work?

"Metoclopramide works by blocking the communication between the CTZ and the vomiting center. This helps to reduce nausea and prevent vomiting. Metoclopramide tablets and liquid typically start working within 30 to 60 minutes."

Answered by AI

Is Gimoti available?

"You can only get GIMOTI through vitaCare Prescription Services. They will give you a call after you have sent in your prescription to set up a delivery."

Answered by AI

Clinical Trials for Gimoti

Image of Arizona State University in Phoenix, United States.

App-based Breathing Program for Migraine

18+
All Sexes
Phoenix, AZ

Migraine is one of the most common neurological disorders, characterized by recurrent headaches, sensitivity to light and movement, nausea, and autonomic dysregulation. Although mind-body interventions like biofeedback have shown their efficacy, they remain underutilized due to barriers such as transportation, time constraints, lack of awareness, stigma, and cost. A targeted approach to enhancing HRV is HRV biofeedback (HRVB), a technique using visual or auditory feedback to help people regulate HRV through slow-paced breathing and positive emotional regulation to promote ANS balance and emotional resilience. Investigators will conduct a remotely delivered pilot RCT of an 8-week, 10 min/day, novel app-based HRVB intervention compared to a sham control intervention (matching intervention time and attention with no biofeedback component) in adult with chronic migraine. Investigators hypothesize data collected from the study will: a) support the feasibility and acceptability of the remotely delivered app-based HRVB intervention among adults with chronic migraine, and b) provide insights into refining the intervention by examining patterns of change in migraine and psychological outcomes from pre- to post-intervention.

Waitlist Available
Online Trial

Arizona State University

Image of Centre hospitalier de l'Université de Montréal (CHUM) in Montreal, Canada.

Aprepitant for Postoperative Nausea and Vomiting

18+
All Sexes
Montreal, Canada

Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis. Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited. This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.

Phase 3
Waitlist Available

Centre hospitalier de l'Université de Montréal (CHUM)

Maxim Roy, MD, FRCPC

Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD

This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.

Waitlist Available
Has No Placebo

Johns Hopkins Medicine

Risheng Xu, MD, PhD

Medtronic

Have you considered Gimoti clinical trials?

We made a collection of clinical trials featuring Gimoti, we think they might fit your search criteria.
Go to Trials
Image of Endeavor Health in Evanston, United States.

Autonomic Neural Blockade for Postoperative Symptoms in Bariatric Surgery

18 - 90
All Sexes
Evanston, IL

The purpose of this research is to evaluate if autonomic nerve block (ANB- blocking pain and nausea signals) decreases pain and anti-nausea medication requirements as well as the experience of pain/nausea during the first 72 hours after sleeve gastrectomy or gastric bypass surgery. Participants will be randomly assigned either to the standard of care or the ANB group before surgery. As part of standard of care, in both groups, laparoscopic bariatric surgery will be initiated with local anesthetic injected into the abdominal wall. In the ANB group, participants will be given an additional injection of local anesthetic medication to block nerves on and around the stomach.

Waitlist Available
Has No Placebo

Endeavor Health

Herbert Hedberg, MD

Image of Mount Sinai Hospital in New York, United States.

Rimegepant + Zavegepant for Migraine

18+
All Sexes
New York, NY

This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting. This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.

Phase 4
Recruiting

Mount Sinai Hospital

Jonathan Schimmel

Pfizer

Have you considered Gimoti clinical trials?

We made a collection of clinical trials featuring Gimoti, we think they might fit your search criteria.
Go to Trials
Image of Mayo Clinic in Rochester in Rochester, United States.

High Resolution Gastric Mapping and Gastroduodenal Manometry for Indigestion

18 - 80
All Sexes
Rochester, MN

Dyspepsia is a common problem attributed to gastric sensorimotor dysfunctions ie, delayed, or less frequently rapid gastric emptying (GE), impaired gastric accommodation, and increased gastric sensation. Therapeutic options manage symptoms, and there is no FDA approved medical therapy for dyspepsia. There is a need for better objective understanding of sensorimotor dysfunction in dyspepsia, as well as noninvasive, efficacious, safe, and inexpensive treatments for dyspepsia. The purpose of this research is to identify disturbances and characterize phenotypes in patients with functional dyspepsia, and to assess the correlations between symptoms (during the manometry and in daily life), gastric emptying, electrical activity (BSGM), and pressure activity (manometry).

Recruiting
Has No Placebo

Mayo Clinic in Rochester

Nicholas R Oblizajek, MD

Image of HCA Florida north florida Hospital in Gainesville, United States.

Bupivacaine Injection for Headache

18+
All Sexes
Gainesville, FL

Headache is a frequent chief complaint among patients presenting to the Emergency Department (ED), accounting for 2.1 million visits annually in the United States. Often, individuals resort to ED care only after over-the-counter or home remedies have failed, leading to the predominant use of intravenous (IV) medications in the ED, including NSAIDs, triptans, neuroleptics, antiepileptics, and dopaminergic antagonists. Unfortunately, these pharmacologic treatments frequently induce side effects such as cognitive impairment, extrapyramidal reactions, and the potential for medication dependency. In the ED, patients frequently require concurrent administration of multiple systemic medications to achieve satisfactory pain relief, thereby elevating the risk associated with medication use. Despite these medication regimens, a significant portion of patients continue to experience inadequate pain relief. Consequently, the search for an optimal headache therapy-characterized by rapid and effective pain relief, long lasting results, minimal side effects, and allows for rapid ED patient turnover-continues to be a popular area of research in emergency medicine. The investigators plan to evaluate the use of 0.5% bupivacaine cervical IM injection at the c6-7 location for the treatment of non traumatic headaches using a non-inferiority design, randomized, prospective, open-label, controlled trial comparing it to physicians choice of intravenous medications in treatment of headache in the Emergency Department at North Florida Hospital.

Phase 3
Waitlist Available

HCA Florida north florida Hospital

Robyn Hoelle, MD

Have you considered Gimoti clinical trials?

We made a collection of clinical trials featuring Gimoti, we think they might fit your search criteria.
Go to Trials